CLINICAL EFFICACY OF SITALIPTIN WITH METMORPHINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CORONARY HEART DISEASE ON THE BACKGROUND OF STATINS

Abstract

Type 2 diabetes mellitus (DM2) is a chronic progressive disease. Experts from the World Diabetes Association predict an increase in the number of patients with diabetes by 2030 by 1.5 times and will reach 552 million people i.e. every 10th inhabitant of the planet will get sick[1]. Half of patients with type 2 diabetes already have complications, including from the cardiovascular system, by the time the disease manifests itself. By the age of 50, almost 50% of diabetic patients have at least one of them unstable angina, myocardial infarction, life-threatening cardiac arrhythmias, and chronic heart failure rapidly develops. In this regard, the main strategy for the treatment of patients with diabetes is to prevent the development of cardiovascular complications, which includes strict control of glycemia, blood pressure, as well as antiplatelet and lipid-lowering therapy.